Sinopharm Shanghai Biomedical Adopts Honeywell Solstice® N40 Refrigerant For Vaccine Cold Storage
2022-04-08
MORRIS PLAINS, N.J., April 6, 2022 – Honeywell today announced that Sinopharm Shanghai Biomedical Co., Ltd., a subsidiary of China National Pharmaceutical Group Co., Ltd. (Sinopharm), has adopted Honeywell Solstice® N40 (R-448A) refrigerant. The energy efficient, low global-warming-potential (GWP) solution will be used for cold storage of Sinopharm vaccines used in Shanghai, including the company’s COVID-19 vaccine.
